Compare Amphastar Pharmaceuticals Inc (AMPH) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Stryker Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Stryker Corporation trades at $346.62 (market cap $132.64B). The key difference: Stryker Corporation is far larger — about 153.5× Amphastar Pharmaceuticals Inc's market cap, and Stryker Corporation pays a 1.02% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SYK | |
|---|---|---|
Market Cap | $863.95M | $132.64B |
Sector | Health | Technology |
52-Week High | $30.81 | $394.34 |
52-Week Low | $16.87 | $282.58 |
Enterprise Value | $1.26B | $144.11B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Stryker (SYK) trades at $339.03, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $3.69 versus $3.49 expected, and demonstrated robust 9% organic sales growth. Analyst consensus is strongly positive with a $379.44 price target and 74% buy ratings. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS robotic technology.
The outlook remains favorable given earnings momentum and product innovation, though risks include competitive pressures and potential cyber disruptions. Valuation multiples such as a P/E of 35.84 suggest premium pricing, requiring sustained growth to justify. Institutional ownership trends show mixed activity, with some funds increasing stakes recently.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
